More Stories

Informist, Thursday, Aug. 14, 2025

By Sunil Raghu

AHMEDABAD – Glenmark Pharmaceuticals Ltd. Thursday reported a massive year-on-year fall in its consolidated net profit for the June quarter due to a substantial one-time cost incurred by the company during the quarter. Glenmark Pharma posted a bottom line of INR 468.71 million for the June quarter, dented by the one-time cost of INR 3.23 billion. Excluding the impact of the one-time cost, the drugmaker's net profit for the quarter was INR 3.7 billion. The net profit, however, rose more than 10 times from a quarter ago as the company had incurred an exceptional cost of INR 3.73 billion in Jan-Mar.

The drugmaker's consolidated revenue for the reporting quarter rose a meagre 0.6% on year to INR 32.64 billion. Sequentially, the revenue was up 0.3%. The company's total expenses during the quarter grew 2.1% on year to INR 28.72 billion, led by a sharp double-digit rise in expenses related to purchases of stock-in-trade. The cost of materials consumed, which is the largest chunk of Glenmark Pharma's expenditure pie, rose 6.8% on year to INR 7.32 billion. Expenses related to purchases of stock-in-trade shot up by 61.5% to INR 5.81 billion. Employee costs grew 7.4% on year to INR 7.63 billion for the quarter and other expenses rose 8.4% to INR 9.06 billion. The company's finance costs for the June quarter rose 47.1% on year to INR 582.26 million.

Glenmark Pharma's consolidated earnings before interest, taxes, depreciation, and amortisation for the June quarter was INR 5.81 billion with an EBITDA margin of 17.8%.

The company's consolidated revenue from India markets during the June quarter was at INR 12.40 billion, up 3.7% on year from INR 11.96 billion. The company said that its India revenue growth was hit due to the discontinuation of tail-end brands and underperformance of diabetes operations during the quarter. The revenue from the North American market fell marginally to INR 7.78 billion from INR 7.81 billion a year ago. The revenue from the European market in the June quarter too fell to INR 6.68 billion from INR 6.96 billion a year ago.

In a bid to strengthen its presence in the consumer care sector and enable sharper strategic focus, the company Thursday approved the transfer of the company's consumer care business to its newly incorporated wholly-owned subsidiary Glenmark Consumer Care Ltd. Glenmark's consumer care business had a turnover of INR 5.15 billion in 2024-25 (Apr-Mar), accounting for 5.6% of its turnover on a standalone basis. The net worth of the business was INR 2.49 billion as on Mar. 31, accounting for 1% of the company's total net worth. The company hopes to complete the transfer by Dec. 31, 2025.

Thursday, shares of the company closed 0.8% higher at INR 2,044.60 on the National Stock Exchange. The company detailed its earnings for the quarter after market hours.  End

Edited by Saji George Titus

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.